☆ 4.2 Article

Apatinib plus paclitaxel versus paclitaxel monotherapy for platinum-resistant recurrent ovarian cancer treatment: A retrospective cohort study

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open- label, multicenter phase 2 basket study

Lingfang Xia et al.

Summary: This study reported the results of camrelizumab in combination with famitinib for the treatment of platinum-resistant ovarian cancer. The combination therapy showed anti-tumor activity and acceptable side effects, suggesting it as a potential alternative treatment strategy in platinum-resistant ovarian cancer.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Oncology

Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer The APPROVE Randomized Clinical Trial

Tiantian Wang et al.

Summary: This study evaluated the efficacy and safety of apatinib plus PLD in treating patients with PROC. The results showed promising efficacy and manageable toxic effects in PROC patients treated with apatinib plus PLD.

JAMA ONCOLOGY (2022)

Add to Collection

Review Integrative & Complementary Medicine

A Comparison of Chemotherapy Used with and without Apatinib for Patients with Ovarian Carcinoma Who Progressed after Standard Regimens: A Systematic Review and Meta-Analysis

Chao Hou et al.

Summary: This meta-analysis compared the combination therapy of apatinib plus chemotherapy with chemotherapy alone in patients with refractory or recurrent ovarian carcinoma. Results showed that apatinib plus chemotherapy significantly improved objective response rate, disease control rate, and overall survival compared to chemotherapy alone.

EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

Ovarian Cancer, Version 2.2020

Deborah K. Armstrong et al.

Summary: Epithelial ovarian cancer is a leading cause of gynecologic cancer death in the United States. The NCCN Guidelines discuss various ovarian cancers, focusing on primary treatment aspects and including recommendations for both common and rare subtypes.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

Add to Collection

Article Oncology

Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN/VEGFR2 signaling axis in ovarian cancer

Yufei Yang et al.

Summary: The study revealed that PD-L1 promotes angiogenesis and metastasis of ovarian cancer by interacting with VEGFR2 and activating the FAK/AKT pathway. The oncogenic transcription factor c-JUN was found to regulate PD-L1 expression, leading to poor prognosis in ovarian cancer patients. Combination therapy of PD-L1 inhibitor and anti-angiogenic drugs may be a potential treatment approach for ovarian cancer.

CANCER COMMUNICATIONS (2021)

Add to Collection

Review Pharmacology & Pharmacy

Advances in the treatment of platinum resistant epithelial ovarian cancer: an update on standard and experimental therapies

Shuk on Annie Leung et al.

Summary: PROC is defined as disease recurrence within 6 months of completing platinum-based chemotherapy, generally associated with poor outcomes and low response rates. Recent developments in therapeutics based on biomarkers and a more nuanced understanding of DNA repair and immunologic pathways have led to novel treatment options, such as PARP inhibitors, cell cycle checkpoint inhibitors, and immune checkpoint inhibitors.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)

Add to Collection

Article Oncology

The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer

Masayuki Sekine et al.

Summary: The study evaluated the usage patterns of bevacizumab administered for platinum-resistant recurrent ovarian cancer in Japan, finding that the regimen of bevacizumab 10 mg/kg every 2 weeks demonstrated efficacy with manageable toxicity profile in patients. Approval of this regimen is clinically desirable for Japanese patients with ovarian cancer.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Review Health Care Sciences & Services

Evaluation of safety and efficacy of apatinib combination with chemotherapy for ovarian cancer treatment: a systematic review and meta-analysis

Jing Qi et al.

Summary: The combination of apatinib with chemotherapy for the treatment of advanced ovarian cancer shows significant improvements in objective response rate (ORR) and disease control rate (DCR) compared to chemotherapy alone, with a lower incidence of adverse effects. However, further verification through high-quality, large sample, and long-term studies is needed due to the limited number of available studies.

ANNALS OF PALLIATIVE MEDICINE (2021)

Add to Collection

Review Oncology

Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review

Rebecca Arend et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2020)

Add to Collection

Review Medicine, Research & Experimental

Therapeutic potentials of Apatinib in cancer treatment: Possible mechanisms and clinical relevance

Nazila Fathi Maroufi et al.

LIFE SCIENCES (2020)

Add to Collection

Review Oncology

Recurrent Treatment in Ovarian Cancer Patients: What Are the Best Regimens and the Order They Should Be Given?

Joanna Glajzer et al.

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2020)

Add to Collection

Editorial Material Oncology

REBECA trial: a new piece of the evidence for bevacizumab in platinum-resistant recurrent ovarian cancer

Daniele Lavacchi et al.

TRANSLATIONAL CANCER RESEARCH (2020)

Add to Collection

Article Oncology

Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: A single-center retrospective study

Wei Chen et al.

CANCER MEDICINE (2020)

Add to Collection

Review Oncology

Epidemiology of ovarian cancer

Patricia Gaona-Luviano et al.

CHINESE CLINICAL ONCOLOGY (2020)

Add to Collection

Review Oncology

Adverse events and management of apatinib in patients with advanced or metastatic cancers: A review

F. Shao et al.

NEOPLASMA (2020)

Add to Collection

Review Oncology

Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives

Eric Pujade-Lauraine et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Review Oncology

Ovarian cancer: Current status and strategies for improving therapeutic outcomes

Ashwin Chandra et al.

CANCER MEDICINE (2019)

Add to Collection

Article Chemistry, Medicinal

Efficacy And Safety Of Apatinib Treatment In Platinum-Resistant Recurrent Epithelial Ovarian Cancer: A Real World Study

Jindi Zhang et al.

DRUG DESIGN DEVELOPMENT AND THERAPY (2019)

Add to Collection

Article Cell Biology

Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with Paclitaxel

Haifeng Qiu et al.

CELL CYCLE (2018)

Add to Collection

Article Obstetrics & Gynecology

Platinum-resistant recurrent ovarian cancer with long survival on bevacizumab and gemcitabine

Shinichi Komiyama et al.

JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (2018)

Add to Collection

Article Biotechnology & Applied Microbiology

Multiline treatment combining apatinib with toptecan for platinum-resistant recurrent ovarian cancer patients: a report of three cases

Yuan Cheng et al.

ONCOTARGETS AND THERAPY (2018)

Add to Collection

Article Oncology

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

Eric Pujade-Lauraine et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

Add to Collection

Article Oncology

Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO)

A. Lortholary et al.

ANNALS OF ONCOLOGY (2012)

Add to Collection

Article Oncology

YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo

Shu Tian et al.

CANCER SCIENCE (2011)

Add to Collection

Article Oncology

Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer

T. Le et al.

GYNECOLOGIC ONCOLOGY (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.